The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).
Farrah Mikhail Datko
No relevant relationships to disclose
Gabriella D'Andrea
No relevant relationships to disclose
Maura N. Dickler
No relevant relationships to disclose
Shari Beth Goldfarb
No relevant relationships to disclose
Maria Theodoulou
Honoraria - Genentech/Roche
Diana Lake
No relevant relationships to disclose
Monica Nancy Fornier
No relevant relationships to disclose
Shanu Modi
No relevant relationships to disclose
Julie Fasano
No relevant relationships to disclose
Elizabeth Anne Comen
No relevant relationships to disclose
Devika Gajria
No relevant relationships to disclose
Mary Ellen Moynahan
No relevant relationships to disclose
Tiffany A. Traina
Consultant or Advisory Role - Genentech/Roche
Melanie Chen
No relevant relationships to disclose
Nicola Hamilton
No relevant relationships to disclose
Sujata Patil
No relevant relationships to disclose
Sarat Chandarlapaty
No relevant relationships to disclose
Clifford Hudis
Research Funding - Merck
Other Remuneration - Estee Lauder Company (I)
Chau T. Dang
Consultant or Advisory Role - Genentech/Roche (U)